Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Atai's ELE-101 Phase 1/2a Trial Update for Depression
Details : ELE-101, a patent-protected IV formulation of psilocin, has been designed to provide consistent and controllable drug delivery in patients with major depressive disorder.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 20, 2024
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Alto Capital Limited
Deal Size : $0.1 million
Deal Type : Private Placement
Details : The proceeds of the Private placement will be used to advance Tryp's research and development program TRYP-0082 (psilocybin) and for general working capital purposes.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
November 10, 2023
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Alto Capital Limited
Deal Size : $0.1 million
Deal Type : Private Placement
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Pharmaceutical Research Unit, Jordan
Deal Size : Inapplicable
Deal Type : Inapplicable
Evaluation of Safety, Rate and Extent of Absorption of Psilocin Mucate
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 13, 2023
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Pharmaceutical Research Unit, Jordan
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I
Sponsor : Beckley Psytech
Deal Size : Undisclosed
Deal Type : Acquisition
Details : The acquisition adds ELE-101, a next-generation, short-duration psychedelic ready for Phase 1 clinical trials, to Beckley Psytech’s pipeline. ELE-101 is an intravenous (IV) formulation of psilocin, the active metabolite of psilocybin.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Undisclosed
October 24, 2022
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I
Sponsor : Beckley Psytech
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Psilocin, is a high-affinity agonist at serotonin 5HT2A receptors, which are especially prominent in the prefrontal cortex for the Treatment of Central Nervous System Disorders.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
October 06, 2022
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ELE-101, a novel, short-acting psychedelic compound which is intended to serve as a possible treatment for depression. ELE-101 was added to Beckley Psytech’s portfolio following the acquisition of Eleusis Therapeutics Limited in October 2022.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
September 11, 2022
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocin,Psilocybine
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Filament Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Comparing the Effects of Psilocin and Psilocybin in Healthy Adults
Details : Undisclosed
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
April 08, 2022
Lead Product(s) : Psilocin,Psilocybine
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Filament Health
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Mydecine Files Full Patent Application Covering Multiple Families of Psilocin Analogs
Details : The application includes solutions to directly address further precision in delivery control and shelf stabilization of psilocin, psilocybin’s active metabolite, both of which are critical for use in the medical setting.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
June 12, 2021
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Mindset has conducted several pharmacological tests on its proprietary synthesized compounds, including a gold-standard functional assay to determine its molecules' functional activity at the human 5HT-2A receptor and other serotonin subtypes.
Product Name : Undisclosed
Product Type : Controlled Substance
Upfront Cash : Inapplicable
August 31, 2020
Lead Product(s) : Psilocin,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Preclinical
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable